🇺🇸 FDA
Patent

US 9833479

Gene correction of SCID-related genes in hematopoietic stem and progenitor cells

granted A61KA61K2035/124A61K35/12

Quick answer

US patent 9833479 (Gene correction of SCID-related genes in hematopoietic stem and progenitor cells) held by Sangamo Therapeutics, Inc. expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Dec 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2035/124, A61K35/12, A61K35/28, A61K35/545